Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer

JAMA

Volumn 297, Issue 21, 2007, Pages 2360-2372

  Kaurah, Pardeep ^a   MacMillan, Andrée ^b   Boyd, Niki ^a   Senz, Janine ^a   De Luca, Alessandro ^a   Chun, Nicki ^c   Suriano, Gianpaolo ^d   Zaor, Sonya ^f   Van Manen, Lori ^g   Gilpin, Cathy ^h   Nikkel, Sarah ^h   Connolly Wilson, Mary ^b   Weissman, Scott ⁱ   Rubinstein, Wendy S ⁱ   Sebold, Courtney ^j,aa   Greenstein, Robert ^k   Stroop, Jennifer ^k   Yim, Dwight ^l   Panzini, Benoit ^m,n   McKinnon, Wendy ^o   Greenblatt, Marc ^o   Wirtzfeld, Debrah ^p   Fontaine, Daniel ^p   Coit, Daniel ^r   Yoon, Sam ^s   Chung, Daniel ^s   Lauwers, Gregory ^s   Pizzuti, Antonio ^t   Vaccaro, Carlos ^u   Redal, Maria Ana ^u   Oliveira, Carla ^d,e   Tischkowitz, Marc ^f,v   Olschwang, Sylviane ^w   Gallinger, Steven ^x   Lynch, Henry ^y   Green, Jane ^q   Ford, James ^c   Pharoah, Paul ^z   Fernandez, Bridget ^b,q   Huntsman, David ^a   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Health Sciences Centre   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PORTO   (Portugal)

^e University of Porto   (Portugal)

^f MCGILL UNIVERSITY   (Canada)

^g KINGSTON GENERAL HOSPITAL   (Canada)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^j WILFORD HALL MEDICAL CENTER   (United States)

^k UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^l Oncology Clinic Moanalua Medical Center   (United States)

^m CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁿ NOTRE DAME HOSPITAL   (Canada)

^o UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^p MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^q MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

^t CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^u HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^v MCGILL UNIVERSITY   (Canada)

^w INSTITUT PAOLI CALMETTES   (France)

^x UNIVERSITY HEALTH NETWORK   (Canada)

^y CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^z UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^aa UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; STOMACH CARCINOMA; UNITED STATES; AGED; CANADA; FOUNDER EFFECT; GENETIC COUNSELING; GENETICS; HETEROZYGOTE; HETEROZYGOTE DETECTION; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; ONSET AGE; PEDIGREE; PENETRANCE; STOMACH TUMOR;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CADHERINS; DNA MUTATIONAL ANALYSIS; FEMALE; FOUNDER EFFECT; GENETIC COUNSELING; GERM-LINE MUTATION; HAPLOTYPES; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MUTATION; NEWFOUNDLAND; PEDIGREE; PENETRANCE; STOMACH NEOPLASMS;

EID: 34249989159     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.21.2360     Document Type: Article

References (56)

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14(suppl 2):ii31-ii36.
2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-362.
4. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21-33.
5. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845-3852.
6. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402-405.
7. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873-880.
8. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508-517.
9. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the e-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11:5401-5409.
10. Frebourg T, Oliveira C, Hochain P, et al. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. J Med Genet. 2006;43:138-142.
11. Dussaulx-Garin L, Blayau M, Pagenault M, et al. A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol. 2001;13:711-715.
12. Oliveira C, Bordin MC, Grehan N, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat. 2002;19:510-517.
13. Humar B, Toro T, Graziano F, et al. Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat. 2002;19:518-525.
14. Suriano G, Oliveira MJ, Huntsman D, et al. E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Hum Mol Genet. 2003;12:3007-3016.
15. Keller G, Vogelsang H, Becker I, et al. Germline mutations in E-cadherin (CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet. 2004;41:e89.
16. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin (CDH1) mutations predispose to familial gastric and colorectal cancer. Hum Mol Genet. 1999;8:607-610.
17. Shinmura K, Kohno T, Takahashi M, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis. 1999;20:1127-1131.
18. Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol. 2005;90:114-133.
19. Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet. 2003;12:575-582.
20. Oliveira C, Suriano G, Ferreira P, et al. Genetic screening for familial gastric cancer. Hereditary Cancer Clin Pract. 2004;2:51-64.
21. Bacani JT, Soares M, Zwingerman R, et al. CDH1/E-cadherin germline mutations in early onset gastric cancer. J Med Genet. 2006;43:867-872.
22. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765-770.
23. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337-342.
24. Oliveira C, Seruca R, Caldas C. Genetic screening for hereditary diffuse gastric cancer. Expert Rev Mol Diagn. 2003;3:201-215.
25. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13:1919-1925.
26. Sarrió D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106:208-215.
27. Oliveira C, Ferreira P, Nabais S, et al. E-cadherin (CDH1) and p53 rather than SMAD4 and caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer. 2004;40:1897-1903.
28. Suriano G, Seixas S, Rocha J, Seruca R. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med. 2006;84:1023-1031.
29. More H, Humar B, Weber W, et al. Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Hum Mutat. 2007;28:203.
30. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086-4089.
31. Kim HC, Wheeler JM, Kim JC, et al. The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal cancer patients in Korea. Gut. 2000;47:262-267.
32. Jonsson BA, Bergh A, Stattin P, Emmanuelsson M, Gronberg H. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer. 2002;98:838-843.
33. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681-687.
34. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863-874.
35. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res. 2002;12:436-446.
36. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991;220:49-65.
37. Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S. Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res. 1996;24:3439-3452.
38. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-1353.
39. Vécsey-Semjén B, Becker KF, Sinski A, et al. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene. 2002;21:4646-4662.
40. Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993;104:1535-1549.
41. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316:1511-1514.
42. Varley JM, McGowan G, Thorncroft M, et al. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet. 1995;32:942-945.
43. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germline E-cadherin mutations. N Engl J Med. 2001;344:1904-1909.
44. Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer. 2001;92:181-187.
45. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130:612-619.
46. van Kouwen MC, Drenth JP, Oyen WJ, et al. [18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res. 2004;10:6456-6459.
47. Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2006;245:873-879.
48. Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4:262-275.
49. Candian Cancer Society. Canadian Cancer Statistics 2006: appendix I, table A3. http://www.ncic.cancer.ca/vgn/images/portal/cit_86751114/31/23/ 935505938cw_2006stats_en.pdf.pdf. Accessibility verified April 26, 2007.
50. Bear JC, Nemec TF, Kennedy JC, et al. Inbreeding in outport Newfoundland. Am J Med Genet. 1988;29:649-660.
51. Larue L, Ohsugi M, Hirchenhain J, Kemler R. E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci U S A. 1994;91:8263-8267.
52. Pfeiffer CJ, Fodor JG, Canning E. An epidemiologic analysis of mortality and gastric cancer in Newfoundland. Can Med Assoc J. 1973;108:1374-1380.
53. Pfeiffer CJ, Threlfall W. Seabirds-a possible environmental factor in gastric cancer in Newfoundland. Digestion. 1977;16:1-9.
54. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-437.
55. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
56. Wolmark N, Dunn BK. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci. 2001;949:99-108.